A new study finds patients want to provide consent before researchers or hospitals use their medical records for research.

Three early-stage cancer drug projects receive pilot grants to help them advance from the bench toward the bedside.

Better shared decision-making could help patients feel more empowered, avoid treatment side-effects and reduce overtreatment.

Researchers characterize three ways in which the gene FOXA1 mutates to trigger prostate cancer.

Cancer biologists and engineers collaborated on a device that could help predict the likelihood of breast cancer metastasis.

Michigan-led research presents a new way of uncovering predictive biomarkers when data from large randomized trials aren’t available.

A 600-patient randomized clinical trial supports pembrolizumab and chemotherapy as a first-line treatment

The largest study of its kind finds societal factors and access to quality care, rather than genetics, underlies higher prostate cancer mortality rates for black men.

A new study finds that U-M-designed compounds led to significantly smaller, slower-growing tumors.

A new approach to RNA sequencing reveals thousands of previously inaccessible RNA fragments in blood plasma that might serve as disease- and organ-specific biomarkers.

A U-M study is the first to define how a little-known type of cell death impacts tumor cells and immune cells.

By capturing more cancer cells than blood draw screening, this device could help doctors understand a tumor’s biology and make decisions about treatment.

Researchers have shown how tumor-associated macrophages release compounds that block gemcitabine in the most common type of pancreatic cancer

A new precision medicine approach developed at the University of Michigan aims to predict cancer’s likelihood of migrating to the brain, and to aid in the search for new treatments

U-M researchers lead the field in successful protein creation, a tactic that could lead to a newer, more effective class of drugs.